Search
Orchestra Biomed Holdings Inc
OBIOAdd to Watchlist
3.745USD
+0.105+2.88%
Close 07-24 16:00（ET）Quotes delayed by 15 min
219.57MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-23The current earnings forecast score of Orchestra Biomed Holdings Inc is 8.00, ranking 69 out of 200 in the Healthcare Equipment & Supplies industry. The average price target is 12.00, with a high of 20.00 and a low of 10.00.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
12.167
Target Price
+229.72%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
88
Total
4
Median
7
Average
Company name
Ratings
Analysts
Orchestra Biomed Holdings Inc
OBIO
7
Boston Scientific Corp
BSX
37
Intuitive Surgical Inc
ISRG
35
Edwards Lifesciences Corp
EW
33
Veeva Systems Inc
VEEV
30
Thermo Fisher Scientific Inc
TMO
30
1
2
3
...
18
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Orchestra Biomed Holdings Inc's expected revenue for the next quarter?
Orchestra Biomed Holdings Inc's expected revenue is 121.40K.
What is Orchestra Biomed Holdings Inc's price target?
Analysts forecast that Orchestra Biomed Holdings Inc's price target is USD 12.00, with the highest forecast at USD 20.00 and the lowest forecast at USD 10.00.
How have Orchestra Biomed Holdings IncOBIO's recent earnings per share performed?
The market expectation was USD -0.33, while Orchestra Biomed Holdings IncOBIO's earnings per share (EPS) for the previous quarter was USD 0.10. EPS for the next quarter is expected at USD -0.39.
What is the analyst rating for Orchestra Biomed Holdings Inc?
Based on the ratings of Orchestra Biomed Holdings Inc's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.